Ed J. Hendricks, M.D.
Clinical Research
Dr. Hendricks believes that physicians have an ethical responsibility to collect results of their treatments, to make careful observations of patient responses and to record these findings as clinical research reports.
Accordingly, with the permission of our patients, we are constantly conducting clinical research, recording our observations and reporting them into the peer-reviewed medical literature.
Published Work & Presentations
1. Hendricks EJ. Off-label drugs for weight management. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;10:223-234.
2. Miguelgorry PL, Hendricks EJ. Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician’s Perspective. Adv Ther. 2016;33(7):1262-1266.
3. Hendricks EJ. The Role of Duromine in Obesity Management – The US experience. New Zealand General Practice Conference & Medical Exhibition; June 10, 2016; Rotorua.
4. Hendricks EJ. Pharmacotherapy, Chapter 8. In: Steelman GM, Westman EC, eds. Obesity, Evaluation and Treatment Essentials. Second ed. Boca Raton, Florida, USA: CRC Press; 2016:137-167.
5. Schmidt SL, Bryman D, Greenway FL, Hendricks EJ. How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals. Obes Surg. 2015;25(1):186-190.
6. Hendricks EJ, Rothman RB, Bryman DA, Schmidt SL. Association of subarachnoid hemorrhage and phentermine usage: Coincidence, not causation. J Am Pharm Assoc (2003). 2015;55(2):122, 124.
7. Hendricks EJ, Rothman RB. The Case of Posterior Reversible Encephalopathy With Intracranial Hemorrhage was Likely due to Uncontrolled Hypertension, and was Unrelated and Coincidental to Long-term Phentermine Use. Neurologist. 2015;19(4):118-119.
8. Hendricks EJ, Greenway F, Schmidt SL, Hendricks MJ, Istratiy Y. Clinical Experience with the Eating Behavior Questionnaire. 65th Annual Symposium of the American Society of Bariatric Physicians; 2015; Washington, D.C. .
9. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. International Journal of Obesity. 2014;38(2):292-298.
10. Hendricks EJ, Schmidt SL, Greenway FL, Istratiy Y, Hendricks MJ. Eating Behavior Questionnaire: Treatment-induced Changes in EBQ Scores. Overcoming Obesity Annual Symposium; September 12, 2014; Austin, Texas.
11. Hendricks EJ, Greenway F, Schmidt SL, Hendricks MJ, Istratiy Y. The Eating Behavior Questionnaire: A novel clinical examination. Obesity Course: Diagnosis to Treatment; March 15, 2014; Philadelphia, PA.
12. Hendricks EJ. Effective medical treatment for obesity In: iNova, ed. iNova Dinner Talks. Adelaide, Perth, Melbourne, Brisbane, Australia: iNova; 2014.
13. Hendricks EJ. The future of weight management. iNova National Obesity Forum; August 10, 2014; Adelaide, Australia.
14. Hendricks EJ. Phentermine – your key questions answered. iNova National Obesity Forum; August 9, 2014; Adelaide, Australia.
15. Hendricks EJ. Forming long-term partnerships to optimise weight management. iNova National Obesity Forum; August 9, 2014; Adelaide, Australia.
16. Seger J, Horn DB, Westman E, et al. ASBP Obesity Algorithm: Adult Adiposity Evaluation & Treatment 2013. 2013; http://asbp.org/obesityalgorithm.html. Accessed October 14, 2013.
17. Schmidt SL, Bryman D, Hendricks EJ, Greenway F. Pharmacotherapy Prescribing Practices Survey: ASBP 2012. Denver: American Society of Bariatric Physicians; 2013.
18. Schmidt SL, Bryman D, Hendricks EJ. Changes in Prescribing Practices of Obesity Medicine Specialists in the United States 2008-2012. ECO 2013; 2013; Liverpool, UK.
19. Hendricks EJ, Greenway F, Srisurapanont M, et al. Long-term Phentermine Pharmacotherapy: An Investigation for Amphetamine-like Phentermine Addiction, Abuse, Cravings, or Withdrawal. ECO 2013; 2013; Liverpool, UK.
20. Hendricks EJ. Copyright: Eating Behavior Questionnaire. Registration Number: TXu 1-894-444 ed: United States Copyright Office; 2013.
21. Hendricks EJ. Pharmacotherapy. Obesity Medicine Certification Review Course; 2013; San Diego.
22. Bryman D, Hendricks EJ, Schmidt SL. Incidence of Addiction and Abuse due to Phentermine, Diethylpropion, and Phendimetrazine in the United States2013, Unpublished manuscript.
23. Hendricks EJ. Trends in U.S.A. Obesity Treatment. Panbesy Asian Conference Tour; 2012, March 9; Chinese University of Hong Kong Medical School, .
24. Hendricks EJ. Treatment of Obesity in the post-Sibutramine Era. What Are the Options? Panbesy Asia Conference Tour; 2012, March 7&8; Seoul, Korea.
25. Schmidt SL, Hendricks EJ. The Use of Pharmacotherapy for Obesity Treatment in the United States. 62nd Annual Obesity and Related Disorders Symposium of the American Society of Bariatric Physicians; October 26, 2012; Orlando.
26. Hendricks EJ, Greenway F, Srisurapanont M, Hendricks MJ, De Marco D. Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Amphetamine-like Phentermine Dependence, Cravings, or Withdrawal. 62nd Annual Obesity and Related Disorders Symposium of the American Society of Bariatric Physicians; 2012; Orlando.
27. Hendricks EJ, Greenway F, Srisurapanont M, De Marco D, Hendricks MJ. Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal: a Prospective trial. 2012. Located at: NCT01402674, Sacramento.
28. Hendricks EJ. Letter by hendricks regarding article, “obesity and cardiovascular disease”. Circulation. 2012;126(12):e191; author reply e192.
29. Hendricks EJ. Using Phentermine, Topiramate, & Qsymia. 62nd Annual Obesity and Related Disorders Symposium of the American Society of Bariatric Physicians; 2012; Orlando.
30. Hendricks EJ. Two Addiction Medicine Studies in Patients treated with phentermine long-term 62nd Annual Obesity and Related Conditions Symposium of the American Society of Bariatric Physicians; October 26, 2012, 2012; Orlando.
31. Hendricks EJ. Cardiovascular Outcomes Trials for New Obesity Drugs. 62nd Annual Obesity and Related Conditions Symposium of the American Society Bariatric Physicians October 26, 2012; Orlando.
32. Hendricks EJ. Treatment of Obesity in the post-Sibutramine Era. What are the Options? Panbesy Asia Conference Tour; March 3, 2012; Singapore.
33. Hendricks EJ, Rothman RB. Phentermine therapy for obesity does not elevate blood pressure. Diabetes Obes Metab. 2011;13(10):963-964.
34. Hendricks EJ, Rothman RB. RE: Pulmonary Hypertension Associated with Use of Phentermine? Yonsei Med J. 2011;52(5):869-870.
35. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351-2360.
36. Hendricks EJ, Greenway FL. A Study of Abrupt Phentermine Cessation in Patients in a Weight Management Program. American Journal of Therapeutics. 2011;18(4):292-299.
37. Hendricks EJ. Should the FDA approval process for weight-loss drugs be modified? Am J Health Syst Pharm. 2011;68(21):2094-2095.
38. Hendricks EJ. Rhabdomyolysis and phentermine: Coincidence, not causation. Am J Health Syst Pharm. 2011;68(15):1386-1395.
39. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19. Int J Cardiol. 2010;145(2):391-392.
40. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19. Int J Cardiol. 2010;145(2):391-392.
41. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety. In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3. Int J Cardiol. 2010;144(2):241-242; author reply 242-243.
42. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety II: Response to Yosefy Int J Cardiol. 2009 Epub Mar 19. Int J Cardiol. 2010;145(2):391-392.
43. Hendricks EJ, Greenway F, Westman E, Gupta AK. Phentermine pharmacotherapy for Weight Management in Overweight to Morbidly Obese Subjects does not alter seated resting office blood pressure 475P Obesity. 2010;18, S2(Supplement 2):S151.
44. Hendricks EJ. Pharmcotherapy, Chapter 8. In: Steelman GM, Westman E, eds. Obesity: Evaluation and Treatment Essentials. First ed. New York, New York: Informa Healthcare; 2010:81-99.
45. Rothman RB, Hendricks EJ. Phentermine Cardiovascular Safety. American Journal of Emergency Medicine. 2009;27(8):1010-1013.
46. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring). 2009;17(9):1730-1735.
47. Hendricks EJ, Greenway FL. Symptoms Observed after Abrupt Phentermine Cessation 223-P. Obesity. 2009;17(Suppl 2):S111.
48. Hendricks EJ, Greenway FL. Symptoms Observed after Abrupt Phentermine Cessation. 27th Annual Scientific Meeting; October 25, 2009; Washington, D.C.
49. Hendricks EJ. Is Phentermine Addicting? 59th Annual Obesity & Associated Conditions Symposium; October 10, 2009, 2009; Costa Mesa.
50. Hendricks EJ, Westman EC. Phentermine Therapy in Obesity Treatment: Effect on Blood Pressure 582P. Obesity. 2008;16, Supplement 1(October):S216.
51. Hendricks EJ, Greenway FL, Westman EC, et al. A Survey of Prescribing Practices of Medical Bariatricians. Obesity. 2008;16(October, Supplement 1):S292-293.
52. Hendricks EJ. Adverse Reactions to Phentermine, Evidence versus Conjecture. 58th Annual Obesity & Associated Conditions Symposium; 2008; Tampa, FL.
53. Hendricks EJ. ASBP Membership Survey of Prescribing Practices. Survey presented at 58th Annual Obesity & Associated Conditions Symposium; May 2008; Tampa, Florida.
54. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 1, 2007; Nashville, TN.
55. Hendricks EJ. “Indications for Phentermine Use in Treating Obesity: Re-examination of Current Guidelines”. Eastern Regional Obesity Course, American Society of Bariatric Physicians; May 4, 2007; Nashville, TN.
56. Hendricks EJ. “Using the Web to Stay Current with Obesity Treatment and Research”. 56th Annual Obesity & Associated Conditions Symposium 2006; San Diego, CA.
57. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 10, 2006; Lexington, KY.
58. Hendricks EJ. Weight Control Pharmacology in Bariatric Surgical Practice. Bariatric Times. Vol 32006:1,16-19.
59. Hendricks EJ, Bryman, D. A., Roldan, E. O. Insurance Panel Debate: Pros and Cons. 55th Annual Obesity & Associated Conditions Symposium; October 31, 2005, 2005; Las Vegas.
60. Hendricks EJ. “New Obesity Drugs: Current Status Report”. Eastern Regional Obesity Course, American Society of Bariatric Physicians; May 12, 2005; Atlanta, GA.
61. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 11, 2005; Atlanta, GA.
62. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 5, 2004, 2004; Scottsdale, AZ.
63. Hendricks EJ. “Pathophysiology of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 4, 2004; Scottsdale, AZ.
64. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board Bariatric Medicine; May 7, 2003; Las Vegas, NV.
65. Hendricks EJ. “New Bariatric Drugs”. Western Regional Obesity Course, American Society Bariatric Physicians; May 10, 2003; Las Vegas, NV
66. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board Bariatric Medicine; May 16, 2002; Denver, CO.
67. Hendricks EJ. “Pathophysiology of Obesity”. Paper presented at: Basic Bariatric Course, American Society Bariatric Physicians; September 17, 2002; Boston, MA.
68. Hendricks EJ. New Drugs for Obesity: Drugs in Phase 2 Clinical Trials. American Journal Bariatric Medicine. 2002;17(2):17-.
69. Hendricks EJ. New Drugs for Obesity: Drugs in Phase 1 Clinical Trials. American Journal Bariatric Medicine. 2002;17(2):16-.
70. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board Bariatric Medicine; April 26, 2001; Atlanta, GA.
71. Hendricks EJ. “New Drugs on the Horizon”. Paper presented at: 51st Annual Obesity & Associated Conditions Symposium, American Society Bariatric Physicians; October 27, 2001; San Diego, CA.
72. Hendricks EJ. New Drugs for Obesity: Drugs in Phase 3 Clinical Trials. American Journal Bariatric Medicine. 2001;16(3):15-.
73. Hendricks EJ. Laboratory computers: tools for increased productivity. Clin Lab Med. 1985;5(4):709-723.
74. Chen KT, Hendricks EJ. Malakoplakia of the female genital tract. Obstet Gynecol. 1985;65(3 Suppl):84S-87S.
75. Hendricks EJ, Langhofer LA. A community hospital laboratory computer system: an eight-year longitudinal study of economic impact. Am J Clin Pathol. 1982;77(3):297-304.
76. Chen KT, Hendricks EJ, Freeburg B. Benign glandular inclusion of the peritoneum associated with leiomyomatosis peritonealis disseminata. Diagn Gynecol Obstet. 1982;4(1):41-44.
77. Hendricks EJ. “The Computerized Laboratory of the Future”. Paper presented at: Symposium on Clinical Decision Making and Laboratory Use, Riyadh-Al-Karj Hospital; January 5, 1981; Riyadh, Saudi Arabia.
78. Chen KT, Hoffman KD, Hendricks EJ. Angiosarcoma following therapeutic irradiation. Cancer. 1979;44(6):2044-2048.
79. Hendricks EJ. “Mechanisms of Subspecialty Training: Where -University or Private Hospital”. Paper presented at: Symposium on the Future of Graduate Medical Education in Pathology, American Society Clinical Pathologists; November, 1976; Monterey, CA.
80. Hendricks EJ. “How Should the Pathologist be Trained to Fulfill His Clinical Role?”. Paper presented at: Symposium on the Future of Graduate Medical Education in Pathology, American Society Clinical Pathologists; November, 1976; Monterey, CA.
81. Simon RG, Langhofer LA, Jr., Hendricks EJ. Australia Antigen Content of Commercial Quality-Control Sera. Clin Chem. 1973;19(2):221-222.
82. Hendricks EJ. “Use of Amniotic Fluid Analysis in Prenatal Management of Rh Disease”. Paper presented at: Annual Meeting, Texas Medical Association; April 1, 1972; Houston, Texas.
83. Hendricks EJ. Quality control in transition; use of computers in the laboratory. Postgrad Med. 1968;44(5):67-69.
84. Hendricks EJ. Methods of blood glucose determination. Postgrad Med. 1967;42(1):A46 passim.
85. Hendricks E. Laboratory Tests of Anterior Pituitary Function. Postgrad Med. 1965;37:A44-52.
Follow us: @hendricks_for_health
Connect with us for tips, recipes and daily inspiration! @hendricks_for_health